Alnylam Pharmaceuticals, Inc. $ALNY Shares Purchased by ProShare Advisors LLC

ProShare Advisors LLC increased its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 4,457.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 211,077 shares of the biopharmaceutical company’s stock after purchasing an additional 206,446 shares during the quarter. ProShare Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $83,935,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of ALNY. Groupama Asset Managment grew its stake in Alnylam Pharmaceuticals by 160.4% during the 3rd quarter. Groupama Asset Managment now owns 4,032,082 shares of the biopharmaceutical company’s stock worth $18,610,000 after purchasing an additional 2,483,697 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its stake in Alnylam Pharmaceuticals by 698.8% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,355,609 shares of the biopharmaceutical company’s stock worth $618,158,000 after purchasing an additional 1,185,909 shares in the last quarter. Qube Research & Technologies Ltd acquired a new position in Alnylam Pharmaceuticals during the 3rd quarter worth $369,943,000. AQR Capital Management LLC grew its stake in Alnylam Pharmaceuticals by 295.2% during the 3rd quarter. AQR Capital Management LLC now owns 744,008 shares of the biopharmaceutical company’s stock worth $336,009,000 after purchasing an additional 555,759 shares in the last quarter. Finally, Orbis Allan Gray Ltd grew its stake in Alnylam Pharmaceuticals by 29.8% during the 2nd quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock worth $691,771,000 after purchasing an additional 486,489 shares in the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Trading Up 2.8%

NASDAQ:ALNY opened at $294.30 on Wednesday. The stock has a 50-day simple moving average of $312.56 and a 200-day simple moving average of $362.08. The stock has a market cap of $39.29 billion, a P/E ratio of 80.41 and a beta of 0.31. Alnylam Pharmaceuticals, Inc. has a 1 year low of $284.19 and a 1 year high of $495.55. The company has a debt-to-equity ratio of 0.94, a quick ratio of 3.06 and a current ratio of 3.13.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.87 by $1.12. The business had revenue of $1.17 billion during the quarter, compared to analysts’ expectations of $1.12 billion. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The business’s quarterly revenue was up 96.4% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.44) EPS. As a group, analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 7.36 earnings per share for the current fiscal year.

Insider Activity

In related news, EVP Jeffrey V. Poulton sold 2,206 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $327.65, for a total transaction of $722,795.90. Following the transaction, the executive vice president owned 64,273 shares in the company, valued at $21,059,048.45. This trade represents a 3.32% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 1,652 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $319.73, for a total value of $528,193.96. Following the transaction, the executive vice president directly owned 21,860 shares in the company, valued at approximately $6,989,297.80. This trade represents a 7.03% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 21,255 shares of company stock worth $6,930,337 over the last ninety days. 0.86% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Wall Street Zen raised Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Needham & Company LLC lowered their price objective on Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating for the company in a research report on Thursday, February 12th. Morgan Stanley lowered their price objective on Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating for the company in a research report on Friday, January 30th. Chardan Capital reaffirmed a “buy” rating and set a $425.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Wednesday, March 25th. Finally, Truist Financial lowered their price objective on Alnylam Pharmaceuticals from $515.00 to $505.00 and set a “buy” rating for the company in a research report on Monday, April 13th. One research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $463.13.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.